VKTX250411P19000
- 0.99
- 0.000.00%
Viking Therapeutics Newsroom
Viking Therapeutics to Report Financial Results for First Quarter 2025 on April 23, 2025
Promising Pipeline and Strategic Developments Drive Buy Rating for Viking Therapeutics
Viking Therapeutics' VK2735 Gains Buy Rating Amid Pfizer's GLP-1 Drug Halt and Promising Trial Results
Pfizer (PFE.US) facing setbacks in research sparks acquisition speculation, stocks of the new weight loss drug rising sharply.
Pfizer (PFE.US) has stopped the development of the highly anticipated oral weight loss drug Danuglipron. Investors are betting that this setback may prompt Pfizer to seek acquisition trades, leading to a rise in the stock prices of several biotechnology companies developing weight loss drugs on Monday.
Nasdaq, S&P, and Dow Closed Higher as Trump Temporarily Shields Tech Sector From Tariffs
Viking Therapeutics Shares Are Trading Higher After Pfizer Discontinued the Development of Danuglipron.
Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Popped Today
Viking, Structure, Metsera on a Tear as Pfizer Drops Obesity Pill
What's Going On With Viking Therapeutics, Structure Therapeutics Stock On Monday?
Viking Seen as Potential Ticket To Get Pfizer Back Into Obesity Game -- Market Talk
Pfizer Stock Falls. It's Halted Development of New Weight-Loss Drug. -- Barrons.com
Express News | Shares of Eli Lilly up 2%, Drug Developer Viking Therapeutics Shares Rise 16.5%
Express News | Shares of U.S. Listed Obesity Drugmakers Rise Premarket After Pfizer to End Development of Its Experimental Weight-Loss Pill
Will Viking Therapeutics Be a Top Healthcare Stock in 10 Years?
The weight loss drug market is "too competitive", and Goldman Sachs gives Viking Therapeutics (VKTX.US) a "neutral" rating.
On Tuesday, Goldman Sachs began coverage of Viking Therapeutics (VKTX.US) with a "neutral" rating, setting a Target Price of $30 per share.
Goldman Sachs Maintains Viking Therapeutics(VKTX.US) With Hold Rating, Maintains Target Price $30
Viking Therapeutics Initiated at Neutral by Goldman Sachs
Viking Therapeutics Draws Neutral Rating at Goldman Sachs on Competitive Headwinds
Goldman Sachs Initiates Viking Therapeutics(VKTX.US) With Hold Rating, Announces Target Price $30
Cautious Hold Rating for Viking Therapeutics Amid Competitive Obesity Market Challenges